Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.50 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SCN1A | P35498 | 1/20 | 0.46 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.46 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1194201 | 1.00 | TSHR (0.52) | TSHRTP53PDCD1CD274LMNA | |
| SCHEMBL582407 | 0.81 | TSHR (0.64) | TSHRTP53PDCD1CD274LMNA | |
| SCHEMBL15253524 | 0.81 | TSHR (0.64) | TSHRTP53PDCD1CD274LMNA | |
| SCHEMBL15253339 | 0.81 | TSHR (0.64) | TSHRTP53PDCD1CD274LMNA | |
| SCHEMBL10974887 | 0.81 | NPC1 (0.54) | TSHRTP53PDCD1CD274LMNA | |
| SCHEMBL8128097 | 0.79 | TSHR (0.57) | TSHRTP53PDCD1CD274LMNA | |
| SCHEMBL14297427 | 0.79 | NPC1 (0.61) | TSHRTP53PDCD1CD274LMNA | |
| SCHEMBL28525420 | 0.79 | TSHR (0.62) | TSHRTP53PDCD1CD274LMNA | |
| SCHEMBL27960013 | 0.78 | TSHR (0.47) | TSHRTP53PDCD1CD274LMNA | |
| SCHEMBL2980323 | 0.78 | LMNA (0.55) | TSHRTP53PDCD1CD274LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12239639-B2 | Cytotoxic actin-targeting compounds | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2025-03-04 | — | — | US | disclosed |
| US-20230037322-A1 | Cytotoxic Actin-Targeting Compounds | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2023-02-09 | — | — | US | disclosed |
| US-20230037322-A1 | Cytotoxic Actin-Targeting Compounds | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2023-02-09 | — | — | US | disclosed |
| US-11369594-B2 | Cytotoxic actin-targeting compounds | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2022-06-28 | — | — | US | disclosed |
| US-11369594-B2 | Cytotoxic actin-targeting compounds | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2022-06-28 | — | — | US | disclosed |
| US-20200306233-A1 | Cytotoxic Actin-Targeting Compounds | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2020-10-01 | — | — | US | disclosed |
| US-7884128-B2 | reacting 11-{[tert-butyl(dimethyl)silyl]oxy}-7-[(E)-2-formyl-1-methyleth-1-en-1-yl]-6,13a-dimethyl-2-phenyl-3a,6,7,10,11,12,13,13a-octahydro-9H-[1,3]dioxolo[4,5-f]oxacyclododecin-9-one with 2-methyl-3-[(1-phenyl-1H-tetrazol-5-yl)sulfonyl]propyl}oxiran-2-yl)pentane-3-ol, to form pladienolide analogues | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-02-08 | — | — | US | disclosed |
| US-7816401-B2 | Process for total synthesis of pladienolide B and pladienolide D | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-20100204490-A1 | PROCESS FOR TOTAL SYNTHESIS OF PLADIENOLIDE B AND PLADIENOLIDE D | KANADA REGINA MIKIE | 2010-08-12 | — | — | US | disclosed |
| EP-1935893-A1 | TOTAL SYNTHESIS OF PLADIENOLIDE B AND PLADIENOLIDE D | Eisai R&D Management Co., Ltd. (JP) | 2008-06-25 | — | — | EP | disclosed |
| US-20080021226-A1 | Process for total synthesis of pladienolide B and pladienolide D | EISAI R&D MANAGEMENT CO., LTD. | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230037322-A1 | Cytotoxic Actin-Targeting Compounds | ACTB, ACTR2, MYC | TSHR 4606/4885TP53 121/4885PDCD1 1092/4885 |
| US-12239639-B2 | Cytotoxic actin-targeting compounds | ACTB, ACTR2, MYC | TSHR 4606/4885TP53 121/4885PDCD1 1092/4885 |
| US-20100204490-A1 | PROCESS FOR TOTAL SYNTHESIS OF PLADIENOLIDE B AND PLADIENOLIDE D | CYP8B1, PLA2G2D, HPD | TSHR 2691/4885TP53 4298/4885PDCD1 3996/4885 |
| US-11369594-B2 | Cytotoxic actin-targeting compounds | ACTB, ACTR2, MYC | TSHR 4606/4885TP53 121/4885PDCD1 1092/4885 |
| US-20200306233-A1 | Cytotoxic Actin-Targeting Compounds | ACTB, ACTR2, MYC | TSHR 4606/4885TP53 121/4885PDCD1 1092/4885 |
| US-20080021226-A1 | Process for total synthesis of pladienolide B and pladienolide D | TPD52L2, CYP8B1, HPD | TSHR 2611/4885TP53 547/4885PDCD1 3040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.